DRACEN PHARMACEUTICALS
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.
DRACEN PHARMACEUTICALS
Social Links:
Industry:
Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Baltimore, Maryland, United States
Country:
United States
Website Url:
http://www.dracenpharma.com
Total Employee:
251+
Status:
Active
Contact:
(917) 398-3710
Email Addresses:
[email protected]
Total Funding:
48.58 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API WordPress Font Awesome Wordpress Plugins Sitelinks Search Box Microsoft Exchange Online Organization Schema
Current Employees Featured
Founder
Investors List
i&i Prague
i&i Prague investment in Series A - Dracen Pharmaceuticals
Deerfield
Deerfield investment in Series A - Dracen Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Dracen Pharmaceuticals
Official Site Inspections
http://www.dracenpharma.com Semrush global rank: 5.8 M Semrush visits lastest month: 1.44 K
- Host name: 149.217.12.198.host.secureserver.net
- IP address: 198.12.217.149
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Dracen Pharmaceuticals"
Dracen Pharmaceutical – At the Convergence of Cancer …
Feb 14, 2024 Our lead candidate, sirpiglenastat (DRP-104), is unique among glutamine inhibitor approaches as it irreversibly inhibits all known enzymes involved in glutamine metabolism …See details»
Leadership – Dracen Pharmaceutical
Our Goal ; Mechanism of Action ; Glutamine-Addicted Tumors ; Pipeline . Clinical TrialsSee details»
Dracen Pharmaceuticals Company Profile | Management and
Www.dracenpharma.com . Dracen Pharmaceuticals Profile and History. Dracen Pharmaceuticals, Inc. is a privately held biotech company developing proprietary anti-cancer drugs that target …See details»
Dracen Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Dracen Pharmaceuticals, Inc. of Cardiff By The Sea, CA. Get the latest business insights from Dun & …See details»
Dracen Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical …
Www.dracenpharma.com. Last update 19 Sep 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. Neoplasms. ...See details»
Dracen Pharmaceuticals - Crunchbase Company Profile …
Contact Email [email protected] Phone Number (917) 398-3710 Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of …See details»
Dracen Pharmaceuticals - Overview, News & Similar companies
Dracen Pharmaceuticals contact info: Phone number: (410) 659-2777 Website: www.dracenpharma.com What does Dracen Pharmaceuticals do? Dracen Pharmaceuticals, …See details»
Dracen Pharmaceuticals - VentureRadar
Website: http://www.dracenpharma.com. Develops proprietary glutamine antagonists for treating cancers, autoimmune, and inflammatory diseases, discovered at Johns ...See details»
Dracen Pharmaceuticals, Inc. | LinkedIn
Dracen Pharmaceuticals, Inc. | 430 followers on LinkedIn. Private biotech company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for …See details»
Dracen Pharmaceuticals - PitchBook
Www.dracenpharma.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. BioLabs San Diego, 10210 Campus Point Drive; Suite 150; San Diego, CA 92121; United StatesSee details»
Working at Dracen Pharmaceuticals - Zippia
Mar 14, 2024 www.dracenpharma.com. Organization Type. Private. CEO. Thomas M. Estok. Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver …See details»
Leadership - Dracen Pharmaceutical
A founding executive of Dracen, Dr. Ragab was most recently the Vice President, Search and Evaluation, Oncology at Bristol-Myers Squibb where he was involved in many major immuno …See details»
Dracen Pharmaceuticals - Craft
Dracen Pharmaceuticals is a biotech company developing drugs in the area of immuno-metabolism. Targeting immuno-metabolism promises to have broad acting effects on …See details»
Dracen Pharmaceutical’s DRP-104 Granted U.S. FDA Fast Track …
Dracen to work closely with FDA to advance the clinical program for the treatment of NSCLC with specific mutations. Dracen Pharmaceuticals, Inc. announced today that the U.S. Food and …See details»
Dracen Pharmaceuticals Stock Price, Funding, Valuation, Revenue ...
Aug 10, 2023 dracenpharma.com. Overview & Products; Financials; People; Total Raised $52.37M. Investors Count 5. Deal Terms 1. Funding, Valuation & Revenue. 5 Fundings. …See details»
Dracen Pharmaceuticals Announces the Initiation of First-in
NEW YORK, Sept. 25, 2020 /PRNewswire-PRWeb/ -- Dracen Pharmaceuticals, Inc., a clinical stage privately-funded biotech company developing anti-cancer drugs, today announced the …See details»
The Fibrolamellar Cancer Foundation (FCF) and Dracen ... - Dracen …
FCF, a public 501(c)(3) nonprofit organization based in Greenwich, CT, was founded in 2009 by Tucker Davis, a FLC patient. Today, FCF is the leading non-governmental funder of FLC …See details»
The Fibrolamellar Cancer Foundation and Dracen Pharmaceuticals …
Feb 27, 2024 [email protected] 201.360.2081 Kate Lazar Deerfield Management [email protected] Office: 212. 583.7278 Cell: 646.791.2998. Kurt Losert Fibrolamellar …See details»
Dracen Pharmaceuticals Announces the Initiation of First-in …
DRP-104, the Company’s novel broad-acting glutamine antagonist, directly targets tumor metabolism and induces profound anti-tumor immune responses.See details»
The Fibrolamellar Cancer Foundation (FCF) and Dracen …
Feb 14, 2024 Greenwich, CT and San Diego, CA – February 14, 2024, The Fibrolamellar Cancer Foundation (FCF) and Dracen Pharmaceuticals Inc., a clinical stage biotech company, …See details»